Description

CA 72-4 is a tumor marker that is commonly used in the diagnosis, monitoring, and management of certain types of cancer, particularly gastric (stomach) cancer. It is a glycoprotein antigen found on the surface of gastric carcinoma cells.

Here are some key points about CA 72-4:

1. Clinical Significance: Elevated levels of CA 72-4 in the blood may indicate the presence of gastric cancer or other gastrointestinal malignancies, such as pancreatic cancer or colorectal cancer. CA 72-4 is particularly useful in the diagnosis and monitoring of advanced or metastatic gastric cancer.
2. Diagnostic Utility: CA 72-4 is often measured in conjunction with other tumor markers, imaging studies (such as computed tomography scans), endoscopic procedures (such as gastroscopy), and histopathological analysis to aid in the diagnosis of gastric cancer and determine the extent of disease.
3. Monitoring Treatment Response: CA 72-4 levels may be monitored over time to assess the response to treatment (such as surgery, chemotherapy, or radiation therapy) and detect disease recurrence or progression. A decrease in CA 72-4 levels following treatment may indicate a favorable response, while increasing levels may suggest treatment failure or disease recurrence.
4. Limitations: While CA 72-4 can be a useful tool in the diagnosis and management of gastric cancer, it is not specific to this disease and can be elevated in other conditions, including benign gastrointestinal disorders, inflammatory conditions, and certain non-gastrointestinal malignancies. Therefore, CA 72-4 levels should be interpreted in conjunction with clinical findings and other diagnostic tests.
5. Serum Levels: Normal reference ranges for CA 72-4 levels can vary between laboratories, but generally, levels above the reference range are considered abnormal. The interpretation of CA 72-4 levels should take into account the patient’s clinical history, symptoms, and other relevant factors.

Overall, CA 72-4 is a valuable tumor marker in the diagnosis and management of gastric cancer, providing clinicians with important information about disease status and treatment response. However, it should be used as part of a comprehensive diagnostic and monitoring strategy and interpreted in the context of the individual patient’s clinical situation.